MICS does not harm the cornea

Article

Microincision cataract surgery (MICS) does not degrade the optical quality of the cornea or induce a modification in corneal astigmatism.

Microincision cataract surgery (MICS) does not degrade the optical quality of the cornea or induce a modification in corneal astigmatism, according to a report published in the January issue of the Journal of Cataract and Refractive Surgery.

Jorge Alio and colleagues from VISSUM, Instituto Oftalmologico de Alicante, Spain conducted a study to examine the effect of MICS on the optical quality of the cornea, characterized in terms of Seidel aberrations. A total of 25 eyes from 25 patients, with nuclear or corticonuclear cataract of grade 2+ to 4+, were enrolled.

MICS was performed using low ultrasound power through a 1.6 to 1.8 mm clear corneal incision placed on the axis of the positive corneal meridian. All eyes received an Acri.Smart 48S (Acri.Tec) intraocular lens (IOL). Seidel aberration root-mean-square (RMS) values were obtained with a 6 mm aperture using the CSO topographer (Costruzione Strumenti Oftalmici) preoperatively and one and three months postoperatively.

The total RMS following MICS decreased from a preoperative mean of 2.15±2.51 µm to 1.96±2.01 µm postoperatively; this decrease was not considered to be statistically significant. Furthermore, the difference between the preoperative corneal astigmatism (-0.80±0.76 D) and postoperative astigmatism (-0.63±0.62 D) was also not considered to be statistically significant, nor were the differences in Seidel aberrations, coma or higher-order aberrations.

The results of this study suggest that MICS does not degrade the optical quality of the cornea or induce a modification in corneal astigmatism.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.